Clinical trials of veine saphÃ¨ne

Clinical trials of veine saphÃ¨ne and meta-analysis are available for the following clinical conditions:

Entry terms: NE21650, NE 21650, NE21650, NE-21650, NE 1530, NE-1530, 3'-sialyllacto-N-neotetraose, sialyl lacto-N-tetraose, 2-(3-pyridinyl)-1-hydroxyethylidene-1,1-phosphonocarboxylic acid, 3-PEHPC, NE 10790, NE10790, NE-10790, NE 10035, NE-10035, (2-acetylthio)ethylidene-1,1-bisphosphonic acid disodium salt, NE 58051, NE-58051, 3-(3-pyridyl)-1-hydroxypropylidene bisphosphonic acid, NE 10244, NE-10244, 2-(N-methyl-3-pyridinyl)-1-hydroxyethylidene bisphosphonic acid, Ptprn2 protein, rat, protein tyrosine phosphatase, receptor type, N polypeptide 2, rat, receptor protein tyrosine phosphatase, NE-6, rat, phogrin protein, rat, protein tyrosine phosphatase, receptor type N, polypeptide 2, rat, PTP NE-6, rat, NE 10133, NE-10133, 1-(((5-(4-chlorophenyl)-2-furanyl)-methylene)amino)-3-(3-(4-(2-hydroxyethyl)-1-piperazinyl)propyl)-2,4-imidazolidinedione dihydrochloride, azimilide, azmilide, NE 10064, NE-10064, azimilide dihydrochloride, 2,4-Imidazolidinedione, 1-(((5-(4-chlorophenyl)-2-furanyl)methylene)amino)-3-(4-(4-methyl-1-piperazinyl)butyl)-, dihydrochloride, 1-(((5-(4-chlorophenyl)-2-furanyl)methylene)amino)-3-(4-(4-methyl-1-piperazinyl)butyl)-2,4-imidazolidinedione dihydrochloride, N,N-dipropyl-2-(4-methoxy-3-(2-phenylethoxy)phenyl)ethylamine monohydrochloride, NE 100, NE-100, N-oleylhomovanillamide, NE 28345, NE-28345, N-oleylhomovanillamide, (E)-isomer, NE 21610, NE-21610, N-((4-(2-aminoethoxy)-3-methoxyphenyl)methyl)-9-octadecenamide, tebufelone, 1-(3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)-5-hexyn-1-one, NE 11740, NE-11740, NE 58095, NE-58095, phosphonic acid, (2-hydroxy-2-(3-pyridinyl)ethylidene)bis-, disodium salt, 2-(3-pyridinyl)-2-hydroxyethylidene-1,1-bisphosphonate, olvanil, N-(3-methoxy-4-hydroxybenzyl)oleamide, NE 19550, NE-19550, 2-(2-pyridyl)ethylidine-1,1-bisphosphonate, 2-PEBP, NE 97221, NE-97221, 2-(2-pyridyl)ethylidine-1,1-bisphosphonate, x sodium salt, 2-(2-pyridyl)ethylidine-1,1-bisphosphonate, monosodium salt, phosmethylan, O,O-dimethyl-S-(N-((2-chlorophenyl)butyramido)methyl)dithiophosphate, NE 79168, NE-79168, (6,7-dihydro-5H-cyclopenta(c)pyridin-7-yl(hydroxy)methylene)bis(phosphonic acid), NE-10501, RLJ-NE-299A, 3-hydroxy-7-methyl-norethynodrel, 3-H-7-M-NE, Nfe2l2 protein, rat, Nrf2 protein, rat (NE-E2-related factor), NF-E2-related factor 2, rat, Nfe2l2 protein, mouse, nuclear factor, erythroid derived 2, like 2 protein, mouse, Nrf2 protein, mouse (NE-E2-related factor), KCNE5 protein, human, Slc6a2 protein, mouse, norepinephrine transporter protein, mouse, solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 protein, mouse, NE transporter protein, mouse, Ne-Osteo, Eudragit NE 30-D, Tempbond NE, 2-furyl-1-nitroethene, 2-Fu-1-NE, Bis(mu-hydroxo)diiron(III), N-(4-nitro-2-hydroxy)phenylmethyl-N-(2-pyridylethyl)-N-(2-pyridylmethyl)amine, bis(mu-hydroxo)diiron(III)(NE)2, DHBT-NE-1, dihydrobenzothiazine-7-(1-hydroxy-2-aminoethyl)-3,4-dihydro-5-hydroxy-2H-1,4-benzothiazine-3-carboxylic acid